In vitro pharmacodynamics and in vivo efficacy of fluconazole, amphotericin B and caspofungin in a murine infection by Candida lusitaniae

Int J Antimicrob Agents. 2014 Feb;43(2):161-4. doi: 10.1016/j.ijantimicag.2013.10.024. Epub 2013 Nov 26.

Abstract

The in vitro activities of fluconazole (FLC), amphotericin B (AmB) and caspofungin (CSP) were evaluated against three isolates of Candida lusitaniae using time-kill curves. AmB showed in vitro fungicidal activity, whilst FLC and CSP exerted mainly strain-dependent fungistatic activity. The in vivo efficacies of the three drugs were evaluated in a murine model of disseminated infection. The doses administered were FLC 50 mg/kg/day, AmB 0.8 mg/kg/day and CSP 5 mg/kg/day. All three drugs were able to reduce the fungal burden in the kidneys of infected mice, with AmB showing the highest efficacy, followed by CSP. At least in this model, FLC, AmB and CSP are good candidates for treating invasive infections by C. lusitaniae.

Keywords: Animal model; Antifungal therapy; Candida lusitaniae; Fungal infection; Murine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphotericin B / therapeutic use*
  • Animals
  • Antifungal Agents / therapeutic use*
  • Candida / drug effects*
  • Candidiasis / drug therapy*
  • Candidiasis / microbiology
  • Caspofungin
  • Colony Count, Microbial
  • Disease Models, Animal
  • Echinocandins / therapeutic use*
  • Fluconazole / therapeutic use*
  • Kidney / microbiology
  • Lipopeptides
  • Male
  • Mice
  • Microbial Sensitivity Tests
  • Treatment Outcome

Substances

  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Amphotericin B
  • Fluconazole
  • Caspofungin